Axis Therapeutics宣布和PharmaEssentia在台灣一起開發TCR-T細胞療法的研究合作
October 13, 2020 14:25 ET
|
Axis Therapeutics Limited
紐約水牛城, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited是Athenex, Inc.（那斯達克代號：ATNX）和Xiangxue Life Sciences Limited（以下稱 “XLifeSc”）的合資公司，主要營運項目是T細胞免疫療法的研究、開發和商品化，今天宣佈與PharmaEssentia...
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
October 12, 2020 16:05 ET
|
Axis Therapeutics Limited
BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the...